<DOC>
	<DOCNO>NCT00664976</DOCNO>
	<brief_summary>This project randomize control trial electroconvulsive therapy ( ECT ) compare treatment usual ( TAU ) treatment treatment resistant depression ( TRD ) bipolar disorder . The purpose trial document effect size , relative effect size adverse effect ECT condition . A specific purpose gain knowledge effect cognitive function .</brief_summary>
	<brief_title>Treatment Resistant Depression Bipolar Disorder - A Randomized Controlled Trial Electroconvulsive Therapy</brief_title>
	<detailed_description>This project randomize control trial electroconvulsive therapy ( ECT ) compare treatment usual ( TAU ) treatment treatment resistant depression ( TRD ) bipolar disorder . The purpose trial document effect size , relative effect size adverse effect ECT condition . A specific purpose gain knowledge effect cognitive function . In national collaboration project investigator compare antidepressant cognitive effect ECT effect drug treatment use condition ; treatment algorithm combine antidepressant , mood stabilizer antipsychotic drug . The investigator use neuropsychological test battery disclose possible ECT induce change cognitive function , investigate long-lasting change . In addition , several study implement inflammatory process pathogenesis depression ; inflammatory process examine function change clinical status treatment modality . The study national collaboration , use Bipolar Research And Innovation Network- BRAIN , patient include BRAIN-study . The study fund Helse Vest RHF , Regional research network mood disorder ( MoodNet ) Norwegian hospital .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Treatment-Resistant</mesh_term>
	<criteria>ECT indicate Diagnosis DSMIVTR Bipolar I Bipolar II disorder verify semistructured diagnostic interview SCID MINI plus . Severity : meet DSMIVTR criterion depressive episode , MADRS 25 . Treatment resistance None response two trial ( lifetime ) mood stabilizer prove efficacy bipolar depression ( lithium , lamotrigine , quetiapine , olanzapine ) /or antidepressant . A trial define least 6 week adequate tolerate dose report patient , patient unable comply 6 week trial mood stabilizer antidepressant . Less 50 % reduction MADRS value still meet DSM IVTR criterion depressive episode Inpatients first week start treatment condition The patient treat psychiatrist hospital whole duration study ( 6 week ) Age â‰¥ 18 Patient competent give inform consent accord judgement clinician Written inform consent Patient fluent Norwegian language Earlier ECT nonresponse ECT within last six month More four fail adequate medication trial current episode Rapid cycling bipolar disorder ( e.g.4 episode per year ) Use medication substance ( pethidine , alcohol , drug ) incompatible drug medication ECT . Such medication must stop least 5 halflives inclusion study . Current use psychotropic medication 5 t1/2 inclusion study period exception follow : The use alimemazine ( max dose 30 mg daily ) , chlorpromazine ( max dose 25 mg x 2 daily ) chlorprotixen ( max dose 20 mg x 2 ) allow . The use mianserin ( max dose 10 mg daily ) allow . Such medication discontinue least 2 day prior neuropsychological assessment . Medication relate ECT procedure allow . Inability comply study protocol Unstable serious medical condition , include clinically relevant laboratory abnormality Conditions affect neuropsychological assessment Parkinson 's Disease , Multiple sclerosis , stroke , alcohol substance abuse dependence ( accord SCID DSMIVTR ) Pregnancy lactation Fertile woman without adequate contraception ( Adequate contraception include : abstinence , oral contraceptive , intrauterine device , barrier method ) YMRS 20 Patient high suicidal risk accord clinician ' judgment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>bipolar depression</keyword>
	<keyword>Electroconvulsive therapy</keyword>
</DOC>